Wearables
[Photo by Filip Mroz on Unsplash]
“2018 will prove to be a landmark year for wearable technology as it continues to carve out its space within mainstream healthcare. Better analytics and more context around the patient will validate the capabilities of these solutions. Sleek design improvements and enhanced usability will make these innovations more integrated than ever before. With over 117 million diagnosed chronic disease patients in the U.S. since 2012, these individuals will be able to adopt these new technologies in their own homes with zero negative impact to their lifestyle. In addition, hospitals will see broader adoption of medical grade wearables to reduce mortality & readmissions for chronic disease patients.” —Ravi Kuppuraj, CEO, Connected Sensing Venture
“The Healthcare Market is on the precipice of a fundamental change in delivery due to the Internet of Things and Generation 2 Wearables/Digital Health. We have reached a point in technological evolution that the introduction of novelty medical-grade sensors, advanced connected medical devices, widespread adoption of smartphones, and use of software automation/analytics, will ultimately enable faster patient testing with better accuracy, ease of usage, and portability.
There is exponentially increasing demand from Hospital Providers, Payors and the Center for Medicare and Medicaid Services for technologically advanced medical devices due to the increasing prevalence of chronic diseases such as heart failure, obesity, diabetes, and hypertension. High compliance connected medical devices enable real-time patient monitoring and help the medical professionals to swiftly respond to patient needs without the need for multiple hospital visits.
The top 10 medical disruptors of 2018>>
You may also like:
|
In the year 2018, device industry must cohesively work more with Pharma companies to add value to the life of the patients. The disease and the disease patterns are changing & so the long term outcomes. Doctors / practitioners/ Companies & regulatory authorities must look at the side effects of post implantation of a device and prescribe medications so that long term outcomes of the patients are better with low side effects. Not all patients globally have an insurance Cover. Adipose tissue derived autologous Stem Cells treatment must get speedy approvals from regulatory authorities.